Clinical Prognosis of Patients With Mild COVID-19 Treated With Casirivimab/Imdevimab in Japan

Aim: This study aimed to report clinical courses of patients who had mild coronavirus disease 2019 (COVID-19), defined as SpO(2) of 96 or higher, and treated with/without casirivimab/imdevimab in Japan, where mortality and number of severe patients were very limited compared to other resource-rich c...

Descripción completa

Detalles Bibliográficos
Autores principales: Osugi, Yasuhiro, Iwata, Hitoshi, Imai, Yasushi, Kobayashi, Daiki, Hirashima, Ryutaro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Internal Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8901141/
https://www.ncbi.nlm.nih.gov/pubmed/35273850
http://dx.doi.org/10.7759/cureus.21882

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8901141/
https://www.ncbi.nlm.nih.gov/pubmed/35273850
http://dx.doi.org/10.7759/cureus.21882

Ejemplares similares